New EU indication for Novartis's Lucentis

 
• By Alexandra Shimmings

Novartis's Lucentis (ranibizumab) has now received EU approval for a fourth indication: choroidal neovascularization (CNV) secondary to pathologic myopia (myopic CNV).

More from New Products

More from Scrip